Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 2525 of 3546 entries
View as:

Bioavailability Study of Candesartan Cilexetil 16mg Tablet Under Fasting Conditions

Phase: N/A Priority: Normal
NCT ID: NCT02006602 Org: User:
Start: 12/13/13 End: 01/22/14 Due: 01/22/15

Utility and Work Productivity Data for Economic Evaluation of Breast Cancer Therapies in the Netherlands and Sweden

Phase: N/A Priority: Normal
NCT ID: NCT01209091 Org: User:
Start: 08/31/09 End: 10/31/09 Due: 10/31/10

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

Phase: N/A Priority: Normal
NCT ID: NCT02453022 Org: User:
Start: 05/18/15 End: 07/31/15 Due: 07/31/16

Study of Subjects With Diabetic Foot Ulcer (DFU)

Phase: N/A Priority: Normal
NCT ID: NCT03153007 Org: User:
Start: 08/11/17 End: 12/06/17 Due: 12/06/18

GSK2190915 Moderate to Severe Asthma Study

Phase: N/A Priority: Normal
NCT ID: NCT00850642 Org: User:
Start: 06/26/09 End: 06/02/10 Due: 06/02/11

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

Phase: N/A Priority: Normal
NCT ID: NCT00799825 Org: User:
Start: 01/01/09 End: 08/02/12 Due: 08/02/13

Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT00086593 Org: User:
Start: 05/31/04 End: 07/31/05 Due: 07/31/06

A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.

Phase: N/A Priority: Normal
NCT ID: NCT01499446 Org: User:
Start: 09/30/03 End: 03/31/04 Due: 03/31/05

ROTAHALER Device Optimization Study

Phase: N/A Priority: Normal
NCT ID: NCT01890863 Org: User:
Start: 08/05/13 End: 09/30/13 Due: 09/30/14

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase: N/A Priority: Normal
NCT ID: NCT01817764 Org: User:
Start: 03/01/13 End: 10/25/13 Due: 10/25/14

Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics

Phase: N/A Priority: Normal
NCT ID: NCT04585009 Org: User:
Start: 10/12/20 End: 06/16/22 Due: 06/16/23

Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)

Phase: N/A Priority: Normal
NCT ID: NCT00413023 Org: User:
Start: 06/30/05 End: 09/30/06 Due: 09/30/07

Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT04975438 Org: User:
Start: 02/10/22 End: 03/09/23 Due: 03/09/24

The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hypersensitivity

Phase: N/A Priority: Normal
NCT ID: NCT01592864 Org: User:
Start: 03/31/12 End: 05/31/12 Due: 05/31/13

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

Phase: N/A Priority: Normal
NCT ID: NCT00607906 Org: User:
Start: 11/16/07 End: 03/10/08 Due: 03/10/09

Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection

Phase: N/A Priority: Normal
NCT ID: NCT01420809 Org: User:
Start: 09/30/07 End: 08/31/09 Due: 08/31/10

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

Phase: N/A Priority: Normal
NCT ID: NCT01323634 Org: User:
Start: 03/18/11 End: 12/14/11 Due: 12/14/12

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

Phase: N/A Priority: Normal
NCT ID: NCT05705440 Org: User:
Start: 02/07/23 End: 01/15/25 Due: 01/15/26

Experimental Dentifrice Remineralization/Fluoride Uptake in an in Situ Model

Phase: N/A Priority: Normal
NCT ID: NCT00752089 Org: User:
Start: 09/30/07 End: 01/31/08 Due: 01/31/09

Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions

Phase: N/A Priority: Normal
NCT ID: NCT02605395 Org: User:
Start: 03/22/14 End: 03/30/14 Due: 03/30/15

Fosamprenavir in Pts With Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT01054586 Org: User:
Start: 01/31/09 End: 03/31/12 Due: 03/31/13

Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa

Phase: N/A Priority: Normal
NCT ID: NCT01954264 Org: User:
Start: 10/19/13 End: 11/25/13 Due: 11/25/14

BONVIVA(Ibandronate) Injection PMS(Post-marketing Surveillance)

Phase: N/A Priority: Normal
NCT ID: NCT01376102 Org: User:
Start: 11/30/07 End: 02/28/13 Due: 02/28/14

First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma

Phase: N/A Priority: Normal
NCT ID: NCT03287310 Org: User:
Start: 10/17/17 End: 07/31/19 Due: 07/31/20

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older

Phase: N/A Priority: Normal
NCT ID: NCT01884519 Org: User:
Start: 07/01/13 End: 08/02/13 Due: 08/02/14